Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Adenocarcinoma or squamous cell carcinoma of the esophagus or G/E junction.~* Must be surgical candidates~* No previous treatment for esophageal cancer~* Must have measurable or evaluable disease~* Able to perform activities of daily living with minimal to no assistance~* Adequate bone marrow, liver and kidney function~* Provide written informed consent~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Tumor location in the proximal esophagus~* Metastatic disease or locally advanced cancer~* Moderate to severe peripheral neuropathy~* Serious pre-existing medical illnesses~* Significant heart disease~* Treated for an invasive cancer within the previous 5 years~* Women who are pregnant or breast-feeding~* Age \< 18 years~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved.
- Cohort 2 (Type: EXPERIMENTAL): Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved.

Based on this trial design, predict the completion outcome and termination type (if applicable).